YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 35-41

  Liu, Yi Nan ^a   Pan, Shiow Lin ^a   Peng, Chieh Yu ^a   Guh, Jih Hwa ^a   Huang, Dong Ming ^a   Chang, Ya Ling ^a   Lin, Chun Hung ^a   Pai, Hui Chen ^a   Kuo, Sheng Chu ^b   Lee, Fang Yu ^c   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Yung Shin Pharmaceutical Industry Co Ltd   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CYCLIC GMP; GELATINASE A; GELATINASE B; MESSENGER RNA; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY INJURY; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HYDROLYSIS KINETICS; IC 50; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOGENESIS INHIBITORS; ANIMALS; BALLOON DILATATION; CAROTID ARTERIES; CYCLIC GMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT DYES; IMMUNOHISTOCHEMISTRY; INDAZOLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 29244492264     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.090563     Document Type: Article

References (30)

1. Bendeck MP, Zempo N, Clowes AW, Galardy RE, and Reidy MA (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75:539-545.
2. Bult H (2000) Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 21:274-279.
3. Cho A and Reidy MA (2002) Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91:845-851.
4. Di Fulvio M, Lauf PK, and Adragna NC (2001) Nitric oxide signaling pathway regulates potassium chloride cotransporter-1 mRNA expression in vascular smooth muscle cells. J Biol Chem 276:44534-44540.
5. Galis ZS, Asanuma K, Godin D, and Meng X (1998) N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97:2445-2453.
6. Galis ZS and Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 90:251-262.
7. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, and Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203.
8. Garas SM, Huber P, and Scott NA (2001) Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 92:165-178.
9. Gomez MP and Nasi E (2000) Light transduction in invertebrate hyperpolarizing photoreceptors: possible involvement of a Go-regulated guanylate cyclase. J Neurosci 20:5254-5263.
10. Imai T, Morita T, Shindo T, Nagai R, Yazaki Y, Kurihara H, Suematsu M, and Katayama S (2001) Vascular smooth muscle cell-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice. Circ Res 89:55-62.
11. Kuzuya M and Iguchi A (2003) Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 10:275-282.
12. Lange RA, Flores ED, and Hillis LD (1991) Restenosis after coronary balloon angioplasty. Annu Rev Med 42:127-132.
13. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, and Collen D (1999) Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 81:799-807.
14. Liu MW, Roubin GS, and King SB 3rd (1989) Restenosis after coronary angioplasty. Circulation 79:1374-1387.
15. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, and Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689.
16. Overall CM and Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657-672.
17. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, and Teng CM (2005) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Heamost 93:940-948.
18. Pan SL, Huang YW, Guh JH, Chang YL, Peng CY, and Teng CM (2003) Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem Pharmacol 65:1897-1905.
19. Pauletto P, Sartore S, and Pessina AC (1994) Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. Clin Sci 87:467-479.
20. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, and Lakatta EG (1994) Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75:41-54.
21. Ramnath N and Creaven PJ (2004) Matrix metalloproteinase inhibitors. Curr Oncol Rep 6:96-102.
22. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, and Newby AC (1996) Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 79:1177-1187.
23. Suzuki T, Suematsu M, and Makino R (2001) Organic phosphates as a new class of soluble guanylate cyclase inhibitors. FEBS Lett 507:49-53.
24. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, and Schafer AI (2002) YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 291:1014-1021.
25. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, and Schafer AI (2000) YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 279:646-652.
26. Wegener JW, Gath I, Forstermann U, and Nawrath H (1997) Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br J Pharmacol 122:1523-1529.
27. Wegener JW and Nawrath H (1997) Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol 323:89-91.
28. Wu CC, Ko FN, Kuo SC, Lee FY, and Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116:1973-1978.
29. Wu CH, Chang WC, Chang GY, Kuo SC, and Teng CM (2004) The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci 94:252-260.
30. Yukihiro H, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, and Shimada K (2001) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161:185-192.